Form 4: Alignment Healthcare CEO Sells Shares Under 10b5-1 Plan

Alignment Healthcare CEO John E. Kao sold 118,000 shares of common stock for approximately $17.48 per share under a pre-arranged trading plan.

Summary

• John E. Kao, Chief Executive Officer and Director of Alignment Healthcare, Inc. (ALHC), reported the sale of 118,000 shares of common stock.
• The transaction took place on March 23, 2026, at a weighted-average price of $17.4783 per share.
• The shares were sold pursuant to a Rule 10b5-1 trading plan, which was adopted on November 21, 2025.
• Individual sales prices for the shares ranged from $17.07 to $17.81.
• Following the reported transaction, Mr. Kao directly holds 1,784,868 shares of common stock.
• Mr. Kao also indirectly holds 2,354,641 shares through the JEK Trust, dated February 8, 2021, where he serves as the trustee.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale was conducted under a pre-arranged 10b5-1 plan, which is a routine financial management practice for executives and does not typically signal a change in company fundamentals.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that insider sales executed under Rule 10b5-1 plans are a common practice for executives to manage personal finances, diversify their holdings, and provide liquidity, often pre-scheduled to avoid any perception of trading on material non-public information. Such transactions are generally viewed as routine and not indicative of a change in the company's fundamental outlook.

Related Party Transactions

• John E. Kao's indirect beneficial ownership of 2,354,641 shares is held by the JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

Stakeholder Impact

• The sale of shares by the CEO under a pre-arranged plan is a routine event with minimal direct impact on shareholders, employees, customers, suppliers, or creditors. It reflects personal financial planning rather than a corporate strategic shift.

Key Dates

Recommendation

The sale by CEO John E. Kao was conducted under a pre-arranged 10b5-1 plan, which is a common practice for executives to manage personal finances and diversify holdings without implying a negative outlook on the company. This transaction alone does not suggest a fundamental shift in the company's prospects or warrant a change in investment recommendation.

Keywords

Alignment Healthcare, ALHC, John E. Kao, Insider Sale, Form 4, 10b5-1 Plan, Common Stock, Executive Compensation